Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Parasitic organism or component thereof or substance...
Reexamination Certificate
2005-02-15
2005-02-15
Smith, Lynette F. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Parasitic organism or component thereof or substance...
C424S185100, C424S191100, C424S199100, C424S265100, C424S272100, C435S069100, C435S069300, C435S173300, C435S320100, C530S350000, C536S023100, C536S023700
Reexamination Certificate
active
06855322
ABSTRACT:
This application is the expression and purification of a recombinantPlasmodium falciparum(3D7) MSP-142. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant MSP-142is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.
REFERENCES:
patent: WO 9730159 (1997-08-01), None
patent: WO 0063245 (2000-10-01), None
Kumar et al 1995, Molecular Medicine 1, 325-332.*
Short Protocols in Molecular Biology Ed: Ausubel Publisher: John Wiley, pp. 10-59, 16-31, 16-32, 16-33 and 16-34.*
Chang et al 1996, Infection and Immunity 64: 253-261.*
Pan et al., “Vaccine Candidate MSP-1 FromPlasmodium Falciparum:A Redesigned 4917 bp Polynucleotide Enables Synthesis And Isolation of Full-Length Protein FromEscherichia ColiAnd Mammalian Cells”, Nucleic Acids Research Oxford University Press, vol. 27(4):1094-1103, (1999).
Chang et al., “A Recombinant Baculovirus 42-Kilodalton C-Terminal Fragment ofPlasmodium FalciparumMerozoite Surface Protein 1 Protects Aotus Monkeys Against Malara”, Infection and Immunity, American Society for Microbiology, vol. 64(1):253-261, (1996).
Kumar et al., “Immunogenicity and In Vivo Efficacy of RecombinantPlasmodium FalciparumMerozoite Surface Protein In Aotus Monkeys”, Molecular Medicine, vol. 1(3):325-332, (1995).
Angov et al., “Process Development for Clinical GradePlasmodium FalciparumMSP1/42 (3D7) Expressed inE. Coli”,XP008018167, p. 207, (1999).
Lalitha et al., “Plasmodium Falciparum:Variations In The C-Terminal Cysteine-Rich Region of the Merozoite Surface Protein-1 In Field Samples Among Indian Isolates”, Experimental Parasitology, Academic Press, vol. 92, pp. 12-18, (1999).
Dutta et al., “Purification, Characterization, And Immunogenicity Of A Disulfide Cross-Linked Plasmodium Vivax Vaccine Candidate Antigen, Merozoite Surface Protein 1, Expressed InEscherichia Coli”, Infection and Immunity, American Society for Microbiology, vol. 69(9):5464-5470, (2001).
Angov et al., “Development And Pre-Clinical Analysis Of APlasmodium FalciparumMerozoite Surface Protein-142Malaria Vaccine”, Molecular & Biochemical Parasitology, vol. 128, pp. 195-204, (2003).
Angov Evelina
Lyon Jeffrey A.
Arwine Elizabeth
Baskar Padma
Smith Lynette F.
The United States of America as represented by the Secretary of
LandOfFree
Isolation and purification of P. falciparum merozoite... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isolation and purification of P. falciparum merozoite..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isolation and purification of P. falciparum merozoite... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3455825